I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and now Xconomy.
The biggest news on the West Coast this week came from Stanford University. The school has lured decorated neuroscientist Marc Tessier-Lavigne away from New York’s Rockefeller University to be the 11th... Read more »
[Corrected, 2/4/16, 2:05pm. See below.] Three weeks ago the world’s biggest genomic sequencing company, Illumina (NASDAQ: ILMN), unveiled a spinout called Grail to make blood tests that could... Read more »
Live longer? How about starting with healthier knees or clearer eyesight?
That’s the proposal from Unity Biotechnology, unveiling itself today with drug programs based upon research into a biological process that,... Read more »
Adicet Bio is launching today with $51 million in Series A cash to make immunotherapies derived from human cells as a treatment for cancer and other diseases. Unlike experimental, personalized products... Read more »
Editas Medicine is pushing ahead with plans to go public. An IPO for the Cambridge, MA-based company would make it the first among the handful of biotechs that are betting on... Read more »
Bad weather has brought parts of the South and the Eastern seaboard to a halt today, but out west, we’re wearing our gumboots and splashing onward. While the rain drums steadily... Read more »
Anyone reading this column should be familiar with the fight over drug prices. Many of you would argue that drug makers are too easy a target in political debates and the... Read more »
[Editor’s note: Deputy Biotechnology Editor Ben Fidler co-wrote this story] The week of the annual J.P. Morgan Healthcare Conference in San Francisco kicked off with a rousing, sleeves-rolled-up defense... Read more »
There’s plenty of speculation whether Allergan CEO Brent Saunders will become CEO of Pfizer—and how quickly—after the two companies’ $160 billion tax-inversion merger, which they hope to consummate later this year.... Read more »
[Updated, 1/11/16. Corrected, 1/20/16. See below.] Microbiome company Seres Therapeutics (NASDAQ: MCRB) has inked a deal with one of its top investors, Nestlé Health Science, that effectively turns... Read more »
As CEO of Cubist Pharmaceuticals, Mike Bonney spent a decade building a mid-cap biotech company that eventually accepted a massive buyout.
Now he’ll be helping start new companies from scratch. Bonney... Read more »
[Corrected, 1/6/16, 8:05pm. See below.] Keith Joung, a scientist at Massachusetts General Hospital in Boston, and his colleagues say they have come up with a way to make the... Read more »
When a biotech company with one product in development misses its milestones, investors typically don’t throw more money at it.
Not so with the newly renamed Millendo Therapeutics. The Ann Arbor,... Read more »
The fight to determine who invented fundamental parts of the CRISPR-Cas9 gene editing technology appears to be headed into a long, arcane battle, the likes of which would never be seen... Read more »
H. Stewart Parker is the former CEO of Seattle’s Targeted Genetics, a pioneering gene therapy company that fizzled out after nearly 20 years but helped pave the way for a new... Read more »
“Synthetic biology” has always been a puzzling term to me. Prosthetic limbs are synthetic. Knee replacements are synthetic. Splicing the gene from one organism into another, a practice that began in... Read more »
March 31, 2016
© 2007-2016, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.